Affiliation:
1. Tyumen State Medical University of the Ministry of Health of the Russian Federation
Abstract
Purpose. To summarize the estimates of the effect of the use of potassium-competitive proton pump inhibitors in pharmacotherapy algorithms for patients with peptic ulcer disease, GERD on treatment outcomes. Material and methods. The most large-scale (as a rule) publications of the last five years devoted to the problem under consideration are analyzed. The search was carried out by keywords in the Pubmed information database (ncbi.nlm.nih.gov). Findings. Potassium-competitive acid blockers (P-CABs), in comparison with «traditional» drugs of this class (proton pump inhibitors), have advantages from a clinical and pharmacoeconomic point of view both in peptic ulcer disease (in particular, as part of eradication therapy) and in gastro-esophageal reflux disease. Confirmation of these data in the conditions of use of K-CCB in patients of the Russian Federation seems appropriate.
Publisher
LLC Global Media Technology
Subject
Gastroenterology,Hepatology
Reference45 articles.
1. Maev I.V., Andreev D. N., Dicheva D. E., Goncharenko A. Yu. Pharmacotherapeutic aspects of the use of proton pump inhibitors. Medical Bulletin of the Ministry of Internal Affairs. 2013; 3(64): 9-14. (In Russ.)@@ Maev I. V., Andreev D. N., Dicheva D. E., Goncharenko A. Yu. Farmakoterapevticheskie aspekty primeneniya ingibitorov protonnoi pompy. Meditsinskii vestnik MVD. 2013; 3(64): 9-14.
2. Mori H., Suzuki H. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker. J Neurogastroenterol Motil. 2019; 25(1): 6-14. doi: 10.5056/jnm18139.
3. Lee K.N., Lee O. Y., Chun H. J. et al. Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis. World J Gastroenterol. 2022; 28(44):6294-6309. doi: 10.3748/wjg.v28.i44.6294.
4. Engevik A.C., Kaji I., Goldenring J. R. The Physiology of the Gastric Parietal Cell. Physiol Rev. 2020; 100(2): 573-602. doi: 10.1152/physrev.00016.2019.
5. Kiyotoki S., Nishikawa J., Sakaida I. Efficacy of Vonoprazan for Helicobacter pylori Eradication.Intern Med. 2020; 59(2): 153-161. doi: 10.2169/internalmedicine.2521-18.